Advertisement

Controversies in Initiating Anti-Retroviral Therapy and in the Use of Combination Therapies

  • Paul A. Volberding
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)

Abstract

Shortly after the human immunodeficiency virus (HIV) was isolated and identified as the causative agent of the acquired immunodeficiency syndrome (AIDS), hope was raised that antiretroviral drugs would prove of value in slowing or reversing the disease process. Some of the first candidate drugs, however, such as suramin and HPA-23, were quickly shown to have no clinical value, despite their having in vitro antiviral activity. With the development of rapid assay systems to evaluate agents in vitro for their ability to inhibit the action of the key viral enzyme, reverse transcriptase, several nucleoside analogs were identified that have subsequently been shown to have clinically important effects. These include several of the currently licensed drugs, such as zidovudine (ZDV), didanosine (ddI), zalcitabine (ddC) and stavudine (d4T).

Keywords

Human Immunodeficiency Virus Human Immunodeficiency Virus Type Human Immunodeficiency Virus Infection Human Immunodeficiency Virus Disease Zidovudine Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 1990; 322: 941–949.PubMedCrossRefGoogle Scholar
  2. 2.
    Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992; 326: 437–443.PubMedCrossRefGoogle Scholar
  3. 3.
    Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel F-D, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329: 297–303.PubMedCrossRefGoogle Scholar
  4. 4.
    Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871–881.CrossRefGoogle Scholar
  5. 5.
    Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng T-C, Fischi MA, Collier AC, Phair JP, Hirsch MS, Hardy WD, Balfour HH, Reiclunan RC for the AIDS Clinical Trials Group. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med, 333; 7: 401–407.Google Scholar
  6. 6.
    Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993; 328: 327–335.PubMedCrossRefGoogle Scholar
  7. 7.
    Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, et al. Massive covert infection of helper.T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 359–362.PubMedCrossRefGoogle Scholar
  8. 8.
    Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123–125.PubMedCrossRefGoogle Scholar
  9. 9.
    Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117–122.PubMedCrossRefGoogle Scholar
  10. 10.
    Richmond D, 1995; Personal communication to Volberding PA.Google Scholar
  11. 11.
    Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173–1225.PubMedCrossRefGoogle Scholar
  12. 12.
    Kinloch-de Loes S, Hirschei BJ, Hoen B, Cooper DA, Tindall B, Can A, Saurat J-H, Clumeck N, Lazzarin A, Mathiesen L, Raffi F, Antunes F, von Overbeck J, Luthy R, Glauser M, Hawkins D, Baumberger C, Yerly S, Perneger TV, Perrin L. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 333; 7: 408–413.Google Scholar
  13. 13.
    Ward J, 1995; Personal communication to Volberding PA.Google Scholar
  14. 14.
    Ho DD. Editorial. Time to hit HIV, early and hard. N Engl J Med 333; 7: 450–451.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Paul A. Volberding

There are no affiliations available

Personalised recommendations